AUTHOR=Hu Yue , Qin Tingting , Li Shuang , Zhang Tao , Xue Jun 

TITLE=Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial

JOURNAL=Frontiers in Oncology

VOLUME=Volume 10 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01589

DOI=10.3389/fonc.2020.01589

ISSN=2234-943X

ABSTRACT=Background: Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) has poor prognosis. Sorafenib/Lenvatinib is recommended as the first-line therapy in these patients currently, with unsatisfactory response and survival benefit reported. Radiotherapy (RT) is increasingly utilized in advanced HCC and is considered an alternative option for HCC patients with PVTT. Combined treatment of RT and locoregional treatments such as transarterial chemoembolization shows promising results. However, the efficacy and safety for combined treatment of RT and systemic therapy has not been reported, and thus warrants further studies. This prospective clinic trial aims at evaluating the efficacy and safety of  SBRT combined with Camrelizumab and Aptinib in HCC patients with PVTT. 
Methods: This multicenter, open-label, random-control trial will enroll 264 HCC patients with PVTT who have not received systemic therapy previously. Stratification of  patients will be based on the presence or absence of extrahepatic metastasis and level of AFP (AFP ≥ 400 ng/mL or < 400 ng/mL) and randomly assigned 1:1 to study and control groups. Patients in study group will receive stereotactic body radiotherapy (SBRT) (95% PTV 36-40 Gy/6-8 Gy), Camrelizumab (200 mg every 2 weeks) and Apatinib (250mg QD), and patients in control group will receive Camrelizumab (200 mg every 2 weeks) and Apatinib (250mg QD). Patients will be followed-up for 1.5 to 3.5 years since the start of therapy. We will use overall survival (OS) as the primary endpoint and  progression-free survival(PFS),  objective response rate(ORR), disease control rate(DCR),  adverse events(AEs) and quality of life（QOL）as the secondary endpoints.
Discussion: This study will be the first random-control trial to assess the efficacy and safety of SBRT combined with Camrelizumab and Apatinib for HCC patients with PVTT. The results may help establish a new standard first-line therapy for these patients.
Trial registration: Chinese Clinical Trial Registration No. ChiCTR1900027102.
Date of registration: October 31, 2019.